Use of propranolol for parotid hemangioma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26676449.
- Also identified by DOI 10.1002/hed.24308.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear. Eighty-seven patients were recruited in this prospective study. Ten patients underwent detailed color Doppler examination. The depths, vessel densities, and resistant indices of 10 lesions were recorded and analyzed before treatment and at 1 and 3 months after treatment. The overall responses were "bad" in 2 cases, "stable" in 4 cases, "good" in 53 cases, and "excellent" in 28 cases. Hemangioma regrowth was observed in 11 cases (12.6%). The parents of 18 patients (20.7%) complained that their children experienced minor discomfort during therapy. The lesion depths, vessel densities, and resistant indices were altered after propranolol treatment. Propranolol can significantly reduce the sizes of parotid hemangiomas with minor side effects. Hemodynamic changes might play an important role in the course of propranolol treatment. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1730-E1736, 2016.
Medical subject headings
- Hemangioma
- Parotid Neoplasms
- Propranolol